326 related articles for article (PubMed ID: 26156157)
1. Engineering New Approaches to Cancer Vaccines.
Mehta NK; Moynihan KD; Irvine DJ
Cancer Immunol Res; 2015 Aug; 3(8):836-43. PubMed ID: 26156157
[TBL] [Abstract][Full Text] [Related]
2. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
3. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
4. Advances in Therapeutic Cancer Vaccines.
Wong KK; Li WA; Mooney DJ; Dranoff G
Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
[TBL] [Abstract][Full Text] [Related]
5. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.
Muraoka D; Harada N; Hayashi T; Tahara Y; Momose F; Sawada S; Mukai SA; Akiyoshi K; Shiku H
ACS Nano; 2014 Sep; 8(9):9209-18. PubMed ID: 25180962
[TBL] [Abstract][Full Text] [Related]
6. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
7. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines.
Schweighoffer T; Schmidt W; Buschle M; Birnstiel ML
Gene Ther; 1996 Sep; 3(9):819-24. PubMed ID: 8875231
[TBL] [Abstract][Full Text] [Related]
8. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
9. Immune response to cancer and its regulation in regional lymph nodes.
Zheng R; Shu S
J Surg Oncol; 2011 May; 103(6):550-4. PubMed ID: 21480248
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
Xia Y; Song T; Hu Y; Ma G
Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
13. Chemical Strategies to Boost Cancer Vaccines.
Li WH; Li YM
Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
[TBL] [Abstract][Full Text] [Related]
14. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.
Zheng R; Kjaergaard J; Lee WT; Cohen PA; Shu S
Cancer Treat Res; 2007; 135():223-37. PubMed ID: 17953420
[No Abstract] [Full Text] [Related]
15. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
17. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
18. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
19. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
Nguyen TL; Choi Y; Kim J
Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
